Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 3 weeks agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks via Yahoo Finance· 6 months agoRoche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone...
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
Zacks via Yahoo Finance· 10 months agoRoche Holding AG’s RHHBY performance in the first half was average, as COVID-19 product related...
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Zacks via Yahoo Finance· 1 year agoRoche Holding AG’s RHHBY performance in 2022 was pretty average, as the demand for COVID-19 products...
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
Zacks via Yahoo Finance· 2 years agoSwiss pharma giant Roche Holding AG’s RHHBY third-quarter revenues declined 6% to CHF 14.7 billion...
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Zacks via Yahoo Finance· 10 months agoSeagen Inc. SGEN announced positive top-line results from its late-stage HER2CLIMB-02 study,...
Symptoms of HER2-Negative Breast Cancer
Verywell Health· 2 years agoMedically reviewed by Douglas A. Nelson, MDMedically reviewed by Douglas A. Nelson, MD Breast cancer occurs when cells within one or both breasts grow...
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
Zacks via Yahoo Finance· 4 months agoRoche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in...
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Zacks via Yahoo Finance· 1 month agoRoche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue...